Specifically, CDK8/19 inhibitors (CDK8/19is) [12] are undergoing clinical trials for both solid tumors and leukemia, as evidenced by entries on www.clinicaltrials.gov (NCT03065010, NCT04021368, NCT05052255, NCT05300438). This evidence concerns the gene CDK8 and leukemia.